Treating Parvovirus in Dogs with Monoclonal Antibodies

Lisa Selvaggio
by Lisa Selvaggio

Canine parvovirus is a serious illness that can be fatal, and treating it is difficult. There’s good news, though, as researchers found a way to target the virus with monoclonal antibodies (mAb)—a step beyond merely managing symptoms.  


The treatment is Canine Parvovirus Monoclonal Antibody (CPMA) from Elanco. Given as a one-time IV injection, it can be used with supportive care to help dogs get over the parvovirus and recover fully. It has been around since 2023 when it was conditionally approved. But, this past June, the USDA expanded access and made it possible to also use this medication to prevent infection in dogs who are exposed to the virus.

Zadoryn/Shutterstock

The monoclonal antibodies of CPMA help a dog’s immune system, showing it how to find and fight the parvovirus. By killing the parvovirus with a targeted medicine, more cases can end successfully, and treatment can be much easier.


Also, if the treatment is started early in the course of the illness, the odds of a dog beating the virus, and avoiding damage to their body from it, are increased.


Previous Research in This Area


A study from 2024 involved 28 puppies who were treated with a placebo or CPMA. None of the dogs that were treated with the CPMA died, while 57% of the dogs treated with the placebo died. Plus, those who received CPMA had less severe symptoms that resolved sooner.


Another study found that dogs who received CPMA had shorter hospitalization times—a median of four days in isolation for untreated dogs versus two days in the hospital if they received the monoclonal antibodies.   


There are some potential adverse reactions to CPMA even though it is overall safe. Those include injection-site reactions, which are mild, along with gastrointestinal effects. Also, this medication is for dogs who are at least 8 weeks old.


Correct Use of CPMA Makes All the Difference


The key is to give the monoclonal antibodies while also providing the tried-and-true supportive care for parvovirus, rather than relying only on CPMA for survival of sick puppies and dogs.


All of this means that, with monoclonal antibodies, shelters and veterinarians can more easily treat parvovirus, getting dogs to feel better sooner and recover sooner than they otherwise would, especially when they are treated as early on in the progression of the illness as possible.


Join the PetGuide community. Get the latest pet news and product recommendations by subscribing to our newsletter here.

Lisa Selvaggio
Lisa Selvaggio

Lisa Selvaggio is a freelance writer and editor, and our resident cats-pert, with certifications in pet nutrition and pet first aid. She enjoys producing content that helps people understand animals better so they can give their pets a safe and happy home.

More by Lisa Selvaggio

Next